Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHIP-AML22 for children and adolescents with newly diagnosed AML
NL-OMON60916Phase 3Recruiting
- Sponsor
- Princess Máxima Center for Pediatric Oncology
- Start
- Jul 2023
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of gemtuzumab ozogamicin in acute myeloid leukemia (AML) (4 arms), sponsored by Princess Máxima Center for Pediatric Oncology. Primary endpoints: Event-free survival, MRD response before induction course 2 and 1 more. Started Jul 2023; status: recruiting.
02
Drugs
gemtuzumab ozogamicin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NL-OMON60916.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60916.